Alfieri C, Tanner J, Carpentier L, Perpête C, Savoie A, Paradis K, Delage G, Joncas J
Department of Microbiology and Immunology, Sainte-Justine Hospital (Pediatric Research Center), Montréal, Quebec, Canada.
Blood. 1996 Jan 15;87(2):812-7.
A previous study (Savoie et al, Blood 83:2715, 1994) identified eight transplant patients who acquired Epstein-Barr virus (EBV) infection during the peritransplant period. Three of these patients subsequently developed B-cell lymphoproliferative disease within 4 months of transplantation. Among these, there was a 16-year-old liver transplant patient who was negative for EBV at the time of transplant and who received an EBV-negative organ. After transplant, this patient was transfused with 9 U of packed red blood cells. Eight of the donors were EBV-positive and one was EBV-negative. We succeeded in obtaining spontaneous lymphoblastoid cell lines (LCLs) from the blood of three of these donors, one of whom also yielded a cord-blood line established with his throat-wash EBV. Blood from a fourth donor did not yield an LCL, but his throat washing did have transforming activity when inoculated onto cord-blood leukocytes. We initially could establish spontaneous LCLs only from the recipient's blood. However, a throat-wash sample taken 11 weeks later did show transforming activity. The recipient was shown to have acquired the EBV infection from one of eight EBV-seropositive blood donors. Analysis of fragment length polymorphisms after polymerase chain reaction amplification of the EBV BamHI-K fragment was used to establish strain identity. Western blot analysis for existence of size polymorphisms in three classes of Epstein-Barr nuclear antigens (EBNA-1, EBNA-2, and EBNA-3) confirmed the DNA results. It is noteworthy that the blood donor responsible for transmitting his EBV strain to the recipient had experienced clinical infectious mononucleosis 15 months before donating blood. Our results may, thus, indicate a requirement for leukodepletion of blood destined for immunosuppressed EBV-negative patients. Finally, blood donors with a recent history of infectious mononucleosis should probably be identified so that their blood is not given to EBV-negative transplant patients.
先前的一项研究(萨沃伊等人,《血液》83:2715,1994年)确定了8名在移植期间感染爱泼斯坦-巴尔病毒(EBV)的移植患者。其中3名患者在移植后4个月内随后发生了B细胞淋巴增殖性疾病。其中有一名16岁的肝移植患者,移植时EBV呈阴性,接受的是EBV阴性的器官。移植后,该患者输注了9单位的浓缩红细胞。8名供血者EBV呈阳性,1名供血者EBV呈阴性。我们成功地从其中3名供血者的血液中获得了自发淋巴母细胞系(LCL),其中1名供血者还用其咽漱液中的EBV建立了脐血系。第四名供血者的血液未产生LCL,但将其咽漱液接种到脐血白细胞上时确实具有转化活性。我们最初只能从受者的血液中建立自发LCL。然而,11周后采集的咽漱液样本确实显示出转化活性。结果表明,受者是从8名EBV血清阳性供血者中的1名那里获得了EBV感染。通过聚合酶链反应扩增EBV BamHI-K片段后分析片段长度多态性,以确定毒株的同一性。对三类爱泼斯坦-巴尔核抗原(EBNA-1、EBNA-2和EBNA-3)中大小多态性的存在进行蛋白质印迹分析,证实了DNA结果。值得注意的是,将其EBV毒株传播给受者的供血者在献血前15个月曾患临床传染性单核细胞增多症。因此,我们的结果可能表明,需要对准备输给免疫抑制的EBV阴性患者的血液进行白细胞去除。最后,可能应该识别近期有传染性单核细胞增多症病史的献血者,以便不将他们的血液输给EBV阴性的移植患者。